News & Updates

Show Multimedia Only
PDE5is do not induce ocular adverse events

PDE5is do not induce ocular adverse events

10 Jan 2024

Use of phosphodiesterase 5 inhibitor (PDE5i) for erectile dysfunction (ED) or benign prostatic hyperplasia (BPD) does not seem to heighten the risk of ocular events in men, reveals a study.

10 Jan 2024